Evexomostat

· SynDevRx, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Evexomostat, covering 2026-04-22 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer [Phase 1, Phase 2]

See pricing